ΠΠ°ΡΠ° Π³ΡΡΠΏΠΏΠ° ΠΎΡΠ³Π°Π½ΠΈΠ·ΡΠ΅Ρ Π±ΠΎΠ»Π΅Π΅ 3000 Π³Π»ΠΎΠ±Π°Π»ΡΠ½ΡΡ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΉ ΠΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ Π² Π‘Π¨Π, ΠΠ²ΡΠΎΠΏΠ΅ ΠΈ Π‘Π¨Π. ΠΠ·ΠΈΡ ΠΏΡΠΈ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠ΅ Π΅ΡΠ΅ 1000 Π½Π°ΡΡΠ½ΡΡ ΠΎΠ±ΡΠ΅ΡΡΠ² ΠΈ ΠΏΡΠ±Π»ΠΈΠΊΡΠ΅Ρ Π±ΠΎΠ»Π΅Π΅ 700 ΠΡΠΊΡΡΡΠΎΠ³ΠΎ Π΄ΠΎΡΡΡΠΏΠ° ΠΡΡΠ½Π°Π»Ρ, Π² ΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ Π±ΠΎΠ»Π΅Π΅ 50 000 Π²ΡΠ΄Π°ΡΡΠΈΡ ΡΡ Π΄Π΅ΡΡΠ΅Π»Π΅ΠΉ, Π°Π²ΡΠΎΡΠΈΡΠ΅ΡΠ½ΡΡ ΡΡΡΠ½ΡΡ , Π²Ρ ΠΎΠ΄ΡΡΠΈΡ Π² ΡΠ΅Π΄ΠΊΠΎΠ»Π»Π΅Π³ΠΈΠΈ.
ΠΡΡΠ½Π°Π»Ρ ΠΎΡΠΊΡΡΡΠΎΠ³ΠΎ Π΄ΠΎΡΡΡΠΏΠ° Π½Π°Π±ΠΈΡΠ°ΡΡ Π±ΠΎΠ»ΡΡΠ΅ ΡΠΈΡΠ°ΡΠ΅Π»Π΅ΠΉ ΠΈ ΡΠΈΡΠΈΡΡΠ΅ΠΌΠΎΡΡΠΈ
700 ΠΆΡΡΠ½Π°Π»ΠΎΠ² ΠΈ 15 000 000 ΡΠΈΡΠ°ΡΠ΅Π»Π΅ΠΉ ΠΠ°ΠΆΠ΄ΡΠΉ ΠΆΡΡΠ½Π°Π» ΠΏΠΎΠ»ΡΡΠ°Π΅Ρ Π±ΠΎΠ»Π΅Π΅ 25 000 ΡΠΈΡΠ°ΡΠ΅Π»Π΅ΠΉ
Efstathia Kalli, Vlamos Panayiotis
Individualized nutritional treatment with polyphenols has been proposed in the early stages of Alzheimer’s disease. However, it remains unclear at what doses polyphenols and their metabolites enter the brain tissue and whether they can act at sufficient concentrations. The present review provides useful insights into the multiple modes of actions of selected polyphenols as potential therapeutic tools at the pre-clinical stage of Alzheimer’s disease, as well as their ability to cross the blood-brain barrier and their detrimental effects after high dose consumptions. Several studies proposed flavonoids for their potential value in prevention and treatment of neurodegenerative diseases. The scarcity of clinical data though highlights the need for conducting metabolomics studies and well-designed clinical trials. Prolonged clinical trials with bioinformatics tools are needed to fully elucidate both neuroprotective effects and possible risks from polyphenol consumption at concentrated high doses.